Cynata Therapeutics' (ASX:CYP) completion of recruitment for its acute graft versus host disease clinical trial provides a clear line of sight to the timing of top-line results from the company's clinical program, the outcome of which is expected to be a major catalyst, Euroz Hartleys said in a note on Monday.

The company completed the enrollment of 65 patients for its phase 2 clinical trial of drug candidate, CYP-001, in adults with high-risk acute graft versus host disease.

The analysts anticipate that the firm's CYP-001 drug candidate could attract "significant" commercial interest if it successfully replicates its first phase results.

The investment firm maintained its speculative buy recommendation and AU$0.90 price target on Cynata Therapeutics.

Cynata Therapeutics' shares jumped about 4% in recent Tuesday trade and earlier hit their highest since August 2022.